Walmsley Shakes Up GSK; Cuts More Than 30 Drug Development Programs

 
• By Lucie Ellis-Taitt

In her first address as CEO, Emma Walmsley has shocked the market with a long list of changes for GSK, including a total makeover of the group's pharma unit. As a result, more than 30 R&D programs will be getting the axe and a 2011 commercialization partnership with Johnson & Johnson is on its way to the gallows.

Blocks
Walmsley to set GSK on a new path with R&D shake up • Source: Shutterstock

More from Earnings

More from Business